

Approved



**Burma**

**Country Operational Plan**

**FY 2016**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
USAID		5,784,000	1,000,000	6,784,000	0	6,784,000
HHS/CDC		2,216,000		2,216,000	1,000,000	3,216,000
<b>Total</b>	<b>0</b>	<b>8,000,000</b>	<b>1,000,000</b>	<b>9,000,000</b>	<b>1,000,000</b>	<b>10,000,000</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency		On Hold Amount	Total
	HHS/CDC	USAID		
HBHC	2,750	273,432	0	276,182
HLAB	71,500		0	71,500
HTXS	704,125	1,200,000	0	1,904,125
HVCT	405,500	1,262,449	0	1,667,949
HVMS	272,500	494,592	0	767,092
HVOP	0	804,047	0	804,047
HVSI	456,875	900,000	0	1,356,875
HVTB	302,750		0	302,750
IDUP		1,013,740	0	1,013,740
OHSS	0	835,740	0	835,740
	<b>2,216,000</b>	<b>6,784,000</b>	<b>0</b>	<b>9,000,000</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	250,000	0
HVTB	300,000	0
<b>Total Technical Area Planned Funding:</b>	<b>550,000</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	66,000	0
HVSI	1,350,000	0
OHSS	800,000	0
<b>Total Technical Area Planned Funding:</b>	<b>2,216,000</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HVCT	1,600,000	0
HVOP	700,000	0
IDUP	950,000	0
<b>Total Technical Area Planned Funding:</b>	<b>3,250,000</b>	<b>0</b>

#### Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	1,900,000	0
<b>Total Technical Area Planned Funding:</b>	<b>1,900,000</b>	<b>0</b>

Approved





### Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	17,044
	Total estimated number of key population in the catchment area	
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9,544
	By key population type:	



	<p>Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>7,500</p>
	<p>By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV</p>	



	preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who	



	inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	10,499
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	



	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	



	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	11
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,893
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,589
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	1
	Test Result by Aggregated Age and Sex: Positive 15+ Male	706



	Test Result by Aggregated Age and Sex: Positive <15 Female	1
	Test Result by Aggregated Age and Sex: Positive 15+ Female	552
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	



	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	190
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	84
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	



	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	10,624
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	



	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	



	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	426
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,477
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	231
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,490
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	40



	Test Result by Aggregated Age and Sex: Positive 15+ Male	648
	Test Result by Aggregated Age and Sex: Positive <15 Female	38
	Test Result by Aggregated Age and Sex: Positive 15+ Female	363
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	



	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	7,516
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	3,108
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	



	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the	183



	reporting period.	
	Total number of registered new and relapsed TB cases, during the reporting period.	227
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with	



	documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	51



	reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	28
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	



	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB	



	cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,108
	Total number of registered new and relapsed TB cases, during the reporting period.	3,885
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator:	



	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered	



	new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	111
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,887
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	74
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,036
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the	



	reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: Total number of	



	registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	80
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	103
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on	



	ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB	



	cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on	1



	ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	



	period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19	



	(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	37
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	111
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	



	the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	37
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	



	period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator:	



	<p>The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB</p>	



	cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	2,031



	Screened for TB by Age/Sex: <15 Male	1
	Screened for TB by Age/Sex: 15+ Male	22
	Screened for TB by Age/Sex: <15 Female	1
	Screened for TB by Age/Sex: 15+ Female	12
	Screen Result: Screened Positive for TB	1
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,391
	Screened for TB by Age/Sex: <15 Male	40
	Screened for TB by Age/Sex: 15+ Male	850



	Screened for TB by Age/Sex: <15 Female	38
	Screened for TB by Age/Sex: 15+ Female	463
	Screen Results: Screened Positive for TB	40
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	40
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	40
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	40
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,969
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	1
	Aggregated Age/Sex: 15+ Male	1,105
	Aggregated Age/Sex: <15 Female	1
	Aggregated Age/Sex: 1-14 Female	



	Aggregated Age/Sex: 15+ Female	862
	Sum of Aggregated Age/Sex <15	2
	Sum of Aggregated Age/Sex 15+	1,967
	Sum of Aggregated Age/Sex disaggregates	1,969
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,391
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	



	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	41
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	850
	Aggregated Age/Sex: <15 Female	38
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	463
	Sum of Aggregated Age/Sex <15	79
	Sum of Aggregated Age/Sex 15+	1,313
	Sum of Aggregated Age/Sex disaggregates	1,392
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,010
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	



	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	1
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	567
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	1
	Aggregated Grouping by Age/Sex: 15+ Female	441
	Sum of Aggregated Age/Sex disaggregates	1,010
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	886
	By Age/Sex: <1	



	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	52
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	513
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	37
	Aggregated Grouping by Age/Sex: 1-14 Female	



	Aggregated Grouping by Age/Sex: 15+ Female	283
	Sum of Aggregated Age/Sex disaggregates	885
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication:	



	10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication:	



	50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	
	Numerator: Indication: Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	
	Denominator: Indication: Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by	



	Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by	



	Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by	



	Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	959
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,067
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	



	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female	



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male	



	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator:	



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
	Aggregated Age/Sex: 15+ Male	9



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	



	those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	505
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	578
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of	



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	



	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of	



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	35
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	324
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	<p>Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>	<p>146</p>
	<p>Aggregated Age/Sex: &lt;15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>35</p>
	<p>Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>361</p>
	<p>Aggregated Age/Sex: &lt;15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and</p>	<p>182</p>

Approved



	those lost to follow-up)	
--	--------------------------	--



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
17110	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,100,000
17111	UNAIDS - Joint United Nations Programme on HIV/AIDS	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	700,000
17112	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	350,000
17114	Population Services International	NGO	U.S. Agency for International Development	GHP-State	2,000,000
18134	TBD	TBD	Redacted	Redacted	Redacted
18135	TBD	TBD	Redacted	Redacted	Redacted
18191	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	400,000

Approved



			Control and Prevention		
18192	TBD	TBD	Redacted	Redacted	Redacted
18193	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	550,000



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 17110</b>	<b>Mechanism Name: ICAP</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,100,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,100,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17110		
<b>Mechanism Name:</b>	ICAP		
<b>Prime Partner Name:</b>	International Center for AIDS Care and Treatment Programs, Columbia University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	250,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVCT	350,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	500,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17111</b>	<b>Mechanism Name: Joint U.N. Programme on HIV/AIDS (UNAIDS III)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 700,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 700,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	700,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 17111</b>
----------------------------



<b>Mechanism Name:</b>	<b>Joint U.N. Programme on HIV/AIDS (UNAIDS III)</b>		
<b>Prime Partner Name:</b>	<b>UNAIDS - Joint United Nations Programme on HIV/AIDS</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	250,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	250,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	200,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17112</b>	<b>Mechanism Name: World Health Organization</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 350,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 350,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	350,000

### Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17112			
<b>Mechanism Name:</b> World Health Organization			
<b>Prime Partner Name:</b> World Health Organization			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	200,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17114	<b>Mechanism Name:</b> Control and Prevention of the Three Diseases CAP-3D
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



<b>Total All Funding Sources: 2,000,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,000,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,000,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17114		
<b>Mechanism Name:</b>	Control and Prevention of the Three Diseases CAP-3D		
<b>Prime Partner Name:</b>	Population Services International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	600,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	350,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	250,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	HTXS	600,000	0
-----------	------	---------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	17,044
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9,544
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	7,500
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	10,499
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	11
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,893
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,589
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	17
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	10,482



HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	10,499
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	706
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	552
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	190
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	84
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	10,624
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	426
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,477
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	231
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,490
HTC_TST_TA	Sum of Aggregated Age/Sex <15	657
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	9,967
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	10,624
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	40
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	648
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	38
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	363
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	7,516



HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	3,108
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	183
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	227
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	51
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	28
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,108
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	3,885
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	111
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,887
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	74
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,036
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART	80

	during TB treatment during the reporting period	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	103
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	37
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	111
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	37
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	2,031
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	22
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	12
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during	1,391



	the reporting period.	
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	40
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	850
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	38
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	463
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	40
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	40
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	40
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	40
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,969
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,105
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	862
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,967
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,969
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,391
TX_CURR_TA	Aggregated Age/Sex: <15 Male	41
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	850
TX_CURR_TA	Aggregated Age/Sex: <15 Female	38
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	463
TX_CURR_TA	Sum of Aggregated Age/Sex <15	79
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,313
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,392
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,010
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	567
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	441
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,010
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	886
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	52
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	513
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	37
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	283
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	885
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	959
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,067
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	505
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	578
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	35
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	324
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	146
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	35
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	361



TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	182
-----------	---	-----

**Implementing Mechanism Details**

Mechanism ID: 18134	TBD: Yes
REDACTED	

**Implementing Mechanism Details**

Mechanism ID: 18135	TBD: Yes
REDACTED	

**Implementing Mechanism Details**

Mechanism ID: 18191	Mechanism Name: Surveillance Technical Support
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 400,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 400,000	
Funding Source	Funding Amount
GHP-State	400,000

**Cross-Cutting Budget Attribution(s)**

Approved



(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 18191			
<b>Mechanism Name:</b> Surveillance Technical Support			
<b>Prime Partner Name:</b> University of California at San Francisco			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	400,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 18192	<b>TBD:</b> Yes
REDACTED	

### Implementing Mechanism Details

<b>Mechanism ID:</b> 18193	<b>Mechanism Name:</b> Global Health Supply Chain Program
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 550,000	
<b>Applied Pipeline Amount:</b> 0	



<b>Total All Funding Sources and Applied Pipeline Amount: 550,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	550,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18193		
<b>Mechanism Name:</b>	Global Health Supply Chain Program		
<b>Prime Partner Name:</b>	Global Health Supply Chain Program		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	550,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Agency Information - Costs of Doing Business**

**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT			15,414	0	15,414	15,414



Services						
ICASS			106,156	0	106,156	106,156
Indirect Costs			33,600	0	33,600	33,600
Management Meetings/Professional Development			22,000	0	22,000	22,000
Non-ICASS Administrative Costs			112,118	0	112,118	112,118
Staff Program Travel			64,492	0	64,492	64,492
USG Staff Salaries and Benefits - Internationally Recruited			389,965	0	389,965	389,965
USG Staff Salaries and Benefits - Locally Recruited			40,255	0	40,255	40,255
<b>Total</b>	<b>0</b>	<b>0</b>	<b>784,000</b>	<b>0</b>	<b>784,000</b>	<b>784,000</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline
-------------------------------	-----	-----------	-----------	------------------	-------	--

Approved



						<b>Amount</b>
Computers/IT Services		10,000		0	10,000	10,000
ICASS		0		65,000	0	65,000
Management Meetings/Professional Development		55,000		0	55,000	55,000
Non-ICASS Administrative Costs		180,000		60,000	180,000	240,000
Staff Program Travel		0		135,000	0	135,000
USG Staff Salaries and Benefits - Internationally Recruited		0		340,000	0	340,000
USG Staff Salaries and Benefits - Locally Recruited		55,000		0	55,000	55,000
<b>Total</b>	<b>0</b>	<b>300,000</b>	<b>0</b>	<b>600,000</b>	<b>300,000</b>	<b>900,000</b>